Advances in medicine are creating new opportunities to identify people at risk of chronic disease and intervene before complications develop. But how can health insurers identify those most likely to benefit from earlier treatment, and what evidence is needed to support investment in prevention?
Join us for an iFHP Executive Briefing featuring a moderated discussion with senior representatives from Eli Lilly and Bupa:
- Professor Rachel Batterham OBE, Senior Vice President, Global Cardiometabolic Health, Eli Lilly
- Ramez Turk, Associate Vice President, Private Ecosystem, Eli Lilly
- Dr Rebecca Rohrer, Clinical Innovation and Genomics Director, Bupa
- Daniel Sullivan, Product & Proposition Director, UK Insurance, Bupa
The discussion will explore how advances in risk identification, targeted prevention and treatment could change the course of cardiometabolic disease, alongside the business case for earlier intervention and opportunities for collaboration between health insurers and pharmaceutical companies.
We have reserved 15 minutes for questions and discussion with members following the 45-minute moderated conversation.
We encourage all interested iFHP members to register in advance to receive the joining details for this online briefing.
Wednesday, 4 November 2026
08:00 GMT | 09:00 CET | 10:00 SAST | 16:00 SGT | 18:00 AEST | 19:00 AEDT | 21:00 NZDT
